Trials / Completed
CompletedNCT01968265
Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes
A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutaneously Once Weekly for 6 Weeks to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCCRRx in combination with metformin versus placebo + metformin
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS-GCCRRx | 3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin |
| DRUG | Placebo | 3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-01-01
- Completion
- 2015-05-01
- First posted
- 2013-10-24
- Last updated
- 2015-05-13
Locations
14 sites across 3 countries: Canada, Romania, South Africa
Source: ClinicalTrials.gov record NCT01968265. Inclusion in this directory is not an endorsement.